SCHEMBL23728803

SCHEMBL23728803

CNCCCN(C)CCCN(C)C(=O)O

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 5/20 0.38
KDM4A O75164 1/20 0.38
HDAC1 Q13547 2/20 0.36
S1PR2 O95136 1/20 0.34
S1PR1 P21453 1/20 0.34
S1PR3 Q99500 1/20 0.34
S1PR5 Q9H228 1/20 0.34
KDM5A P29375 4/20 0.34
SIGMAR1 Q99720 6/20 0.33
TMEM97 Q5BJF2 5/20 0.33
KDM5C P41229 1/20 0.33
KDM5B Q9UGL1 1/20 0.33
PRMT3 O60678 1/20 0.33
CARM1 Q86X55 1/20 0.33
PRMT6 Q96LA8 1/20 0.33
PRMT1 Q99873 1/20 0.33
PRMT8 Q9NR22 1/20 0.33
APP P05067 1/20 0.33
ACKR3 P25106 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3713274 0.92 KDM4A (0.42) KDM4CKDM4AHDAC1PRMT3CARM1
SCHEMBL10045279 0.81 PRMT3 (0.48) KDM4CKDM4AS1PR2S1PR1S1PR3
SCHEMBL2189591 0.79
SCHEMBL1231390 0.78 PRMT3 (0.50) KDM4CKDM4AS1PR2S1PR1S1PR3
SCHEMBL28903229 0.78 NOS3 (0.38) APP
SCHEMBL910571 0.78 EPHX1 (0.54) KDM4CKDM4AS1PR2S1PR1S1PR3
SCHEMBL29300379 0.78 KISS1R (0.36) KDM4CKDM4AS1PR2S1PR1S1PR3
SCHEMBL23728793 0.76 CA14 (0.41) HDAC1
SCHEMBL469832 0.76 PRMT3 (0.48) KDM4CKDM4AS1PR2S1PR1S1PR3
SCHEMBL16317337 0.76 PRMT3 (0.48) KDM4CKDM4AS1PR2S1PR1S1PR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4100404-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. (US) 2022-12-14 EP disclosed
WO-2021158707-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. (US) 2021-08-12 WO disclosed